Vaccine-Preventable Diseases: Viral
CDC Yellow Book 2024
Travel-Associated Infections & DiseasesTable 5-08 Vaccine-Preventable Diseases: Viral
|
VACCINE |
TRADE NAME (MANUFACTURER) |
DESCRIPTION1 & ROUTE OF ADMINISTRATION |
AGE LIMITS |
DOSES |
PRESCRIBING & BOOSTER INFORMATION, RECOMMENDATIONS & RESTRICTIONS |
|---|---|---|---|---|---|
|
COVID-19 |
COMIRNATY (Pfizer-BioNTech) |
mRNA, IM |
≥6 months | ||
|
COVID-19 |
SPIKEVAX (Moderna) |
mRNA, IM |
≥6 months | ||
|
COVID-19 |
NOVAVAX (Novavax) |
Recombinant, IM |
≥12 years | ||
|
Dengue |
DENGVAXIA (Sanofi Pasteur) |
Live-attenuated, SC |
9–16 y |
3 |
Restrictions apply DENGVAXIA |
|
Ebola Zaire |
ERVEBO (Merck) |
Live-attenuated, IM |
≥18 y |
1 |
Restrictions apply |
|
Enterovirus-A71 (Hand, Foot & Mouth) |
Available in China only |
||||
|
Hepatitis A |
HAVRIX (GlaxoSmithKline) |
Inactivated, IM |
0.5 mL |
||
|
≥12 mo to <19 y |
2 |
||||
|
Hepatitis A |
HAVRIX (GlaxoSmithKline) |
Inactivated, IM |
1.0 mL |
||
|
≥19 y |
2 |
||||
|
Hepatitis A |
VAQTA (Merck) |
Inactivated, IM |
0.5 mL |
||
|
≥12 mo to <19 y |
2 |
||||
|
Hepatitis A |
VAQTA (Merck) |
Inactivated, IM |
1.0 mL |
||
|
≥19 y |
2 |
||||
|
Hepatitis A + Hepatitis B |
TWINRIX (GlaxoSmithKline) |
Inactivated HAV + Recombinant HBV, IM |
STANDARD DOSING |
||
|
≥18 y |
3 |
||||
|
Hepatitis A + Hepatitis B |
TWINRIX (GlaxoSmithKline) |
Inactivated HAV + Recombinant HBV, IM |
ACCELARATED DOSING |
||
|
≥18 y |
3 (+ booster) |
||||
|
Hepatitis B |
ENGERIX-B (GlaxoSmithKline) |
Recombinant, IM |
<20 y |
3 |
|
|
≥20 y |
3 |
||||
|
Hepatitis B |
HEPLISAV-B (Dynavax Technologies) |
Recombinant, IM |
≥18 y |
2 |
|
|
Hepatitis B |
PREHEVBRIO (VBI Vaccines) |
Recombinant, IM |
≥18 y |
3 |
|
|
Hepatitis B |
RECOMBIVAX HB (Merck) |
Recombinant, IM |
Less than 20 y |
3 |
|
|
Influenza |
For the list of influenza vaccines licensed for use in the United States, see: Vaccines Licensed for Use in the United States |
||||
|
Japanese encephalitis |
IXIARO (Valneva) |
Inactivated, IM |
0.25 mL |
||
|
≥2 mo to <3 y |
2 |
||||
|
Japanese encephalitis |
IXIARO (Valneva) |
Inactivated, IM |
0.5 mL |
||
|
≥3 y |
2 |
||||
|
Mumps |
M-M-R II (Merck) |
Live-attenuated, SC |
<12 mo |
3 |
Measles, Mumps and Rubella Virus Vaccine Live |
|
≥12 mo |
2 |
||||
|
Mumps |
ProQuad (Merck) |
Live-attenuated, SC |
≥12 mo to <13 y |
2 |
PROQUAD |
|
Polio |
IPOL (Sanofi Pasteur) |
Inactivated, IM or SC |
CHILDREN |
IPOL - Poliovirus Vaccine Inactivated (Monkey Kidney Cell) |
|
|
≥6 wks |
3 |
||||
|
ADULTS TRAVELING TO AREAS WITH INCREASED RISK OF POLIO |
|||||
| UNVACCINATED, PARTLY VACCINATED, VACCINATION STATUS UNKNOWN | |||||
|
≥18 y |
3 |
||||
| COMPLETELY VACCINATED | |||||
|
≥18 y |
1-time booster |
||||
|
Rabies |
IMOVAX (Sanofi Pasteur) |
Inactivated (human diploid cell), IM |
all ages |
2–3 |
|
|
Rabies |
RabAvert (Novartis) |
Inactivated (purified chick embryo cell), IM |
all ages |
2–3 |
RabAvert - Rabies Vaccine |
|
Rubella |
M-M-R II (Merck) |
Live-attenuated, SC |
<12 mo |
3 |
Measles, Mumps and Rubella Virus Vaccine Live |
|
≥12 mo |
2 |
||||
|
Rubella |
ProQuad (Merck) |
Live-attenuated, SC |
≥12 mo to <13 y |
2 |
PROQUAD |
|
Rubeola / Measles |
M-M-R II (Merck) |
Live-attenuated, SC |
<12 mo |
3 |
Measles, Mumps and Rubella Virus Vaccine Live |
|
≥12 mo |
2 |
||||
|
Rubeola / Measles |
ProQuad (Merck) |
Live-attenuated, SC |
≥12 mo to <13 y |
2 |
PROQUAD |
|
Tick-borne encephalitis |
TICOVAC (Pfizer) |
Inactivated, IM |
0.25 mL |
||
|
≥1–15 y |
3 |
||||
|
Tick-borne encephalitis |
TICOVAC (Pfizer) |
Inactivated, IM |
0.5 mL |
||
|
≥16 y |
3 |
||||
|
Varicella / Chickenpox |
VARIVAX (Merck) |
Live-attenuated, SC |
1–12 y |
2 |
VARIVAX (refrigerated and frozen formulations) |
|
≥ 13 y |
2 |
||||
|
Varicella / Chickenpox |
ProQuad (Merck) |
Live-attenuated, SC |
≥12 mo to <13 y |
2 |
PROQUAD |
|
Variola / Smallpox + Mpox |
ACAM2000 (Emergent BioSolutions) |
Live-attenuated vaccinia virus, percutaneous via bifurcated needle |
all ages |
1 |
Restrictions apply ACAM2000 |
|
Variola / Smallpox + Mpox |
JYNNEOS (Bavarian Nordic) |
Live-attenuated non-replicating vaccinia virus, SC |
≥18 y |
2 |
Restrictions apply JYNNEOS |
|
Yellow Fever |
YF-VAX (Sanofi Pasteur) |
Live-attenuated, SC |
≥9 mo |
1 |
|
Abbreviations: IM, intramuscular; SC, subcutaneously
1For an overview and description of vaccine types, see: www.hhs.gov/immunization/basics/types/index.html